This fact, together with the different susceptibility of brain regions to the development of tau-related pathologies, such as Alzheimer’s disease [39] or paranuclear superior palsy [57] and the region-specific nature of other tauopathy-related mechanisms, such as Tau post-translational modifications [58] underline the importance of considering also regional variability of Tau isoforms and their potential role in determining such differential vulnerability. The gene discussed is MAPT; the disease is tauopathy.